Altimmune, Inc. financial data

Symbol
ALT on Nasdaq
Location
910 Clopper Road, Suite 201 S, Gaithersburg, MD
State of incorporation
DE
Fiscal year end
December 31
Former names
PHARMATHENE, INC (to 5/3/2017), HEALTHCARE ACQUISITION CORP (to 10/15/2007)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.51K % +21.4%
Debt-to-equity 10.3 % -4.98%
Return On Equity -63.4 % -35.6%
Return On Assets -57.5 % -36.3%
Operating Margin -215K % -603%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71.1M shares +32.4%
Common Stock, Shares, Outstanding 71.1M shares +34.6%
Entity Public Float 184M USD -65.7%
Common Stock, Value, Issued 7K USD +40%
Weighted Average Number of Shares Outstanding, Basic 71.1M shares +32.5%
Weighted Average Number of Shares Outstanding, Diluted 71.1M shares +32.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 52K USD -81.4%
Revenue from Contract with Customer, Excluding Assessed Tax 3.48M USD -44.2%
Research and Development Expense 79.4M USD +16.6%
General and Administrative Expense 20.2M USD +14.8%
Operating Income (Loss) -112M USD -31.1%
Nonoperating Income (Expense) 8.41M USD +21.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -20.7M USD +12.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -104M USD -31.9%
Earnings Per Share, Basic -1.56 USD/shares +1.27%
Earnings Per Share, Diluted -1.56 USD/shares +1.27%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 31.5M USD -63.8%
Assets, Current 146M USD -4.71%
Property, Plant and Equipment, Net 446K USD -41.7%
Operating Lease, Right-of-Use Asset 1.66M USD +291%
Intangible Assets, Net (Excluding Goodwill) 0 USD -100%
Other Assets, Noncurrent 1.66M USD +290%
Assets 148M USD -11.2%
Accounts Payable, Current 1.13M USD -62.8%
Employee-related Liabilities, Current 2.31M USD -4.66%
Liabilities, Current 8.64M USD -27.2%
Operating Lease, Liability, Noncurrent 1.46M USD +382%
Other Liabilities, Noncurrent 26K USD -43.5%
Liabilities 14.5M USD -10.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4.85M USD +5.45%
Retained Earnings (Accumulated Deficit) -538M USD -23.8%
Stockholders' Equity Attributable to Parent 133M USD -11.3%
Liabilities and Equity 148M USD -11.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.4M USD +15.7%
Net Cash Provided by (Used in) Financing Activities -261K USD +13.6%
Net Cash Provided by (Used in) Investing Activities -39.5M USD -397%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 71.1M shares +34.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -56.1M USD -776%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 31.5M USD -63.7%
Deferred Tax Assets, Valuation Allowance 83M USD +44.9%
Deferred Tax Assets, Gross 83.1M USD +37.8%
Operating Lease, Liability 1.77M USD +125%
Depreciation 107K USD -14.4%
Payments to Acquire Property, Plant, and Equipment 51K USD +467%
Lessee, Operating Lease, Liability, to be Paid 2.26M USD
Property, Plant and Equipment, Gross 2.63M USD +1.82%
Operating Lease, Liability, Current 313K USD -35.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 376K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 422K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +27.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 491K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 387K USD
Deferred Tax Assets, Operating Loss Carryforwards 54.1M USD +21.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 711K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 398K USD
Operating Lease, Payments 100K USD 0%
Additional Paid in Capital 676M USD +14.6%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 119K USD +60.8%
Deferred Tax Assets, Net of Valuation Allowance 98K USD -96.8%
Share-based Payment Arrangement, Expense 13.5M USD +11.7%
Interest Expense 34K USD -50%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%